MLTX Relative Valuation
MLTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MLTX is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.00
P/B
Median3y
Median5y
0.00
FCF Yield
Median3y
Median5y
Competitors Valuation Multiple
The average P/S ratio for MLTX's competitors is 492.75, providing a benchmark for relative valuation. MoonLake Immunotherapeutics Corp (MLTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is MoonLake Immunotherapeutics (MLTX) currently overvalued or undervalued?
What is MoonLake Immunotherapeutics (MLTX) fair value?
How does MLTX's valuation metrics compare to the industry average?
What is the current P/B ratio for MoonLake Immunotherapeutics (MLTX) as of Apr 27 2025?
What is the current FCF Yield for MoonLake Immunotherapeutics (MLTX) as of Apr 27 2025?
What is the current Forward P/E ratio for MoonLake Immunotherapeutics (MLTX) as of Apr 27 2025?